Physician profile
David A Picone
NPI 1568575579
$2,467.33
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $831 · 2021: $918 · 2022: $71.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $536.05 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $336.58 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $312.00 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $251.34 | 2019-2021 | |
| Lundbeck LLC | $242.23 | 2019-2022 | |
| Abbvie INC. | $111.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $93.01 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.97 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $74.25 | 2020-2021 | |
| Neuronetics, INC. | $71.30 | 2019-2020 | |
| Allergan, INC. | $58.42 | 2019-2020 | |
| Eisai INC. | $54.77 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.73 | 2021 | |
| Alkermes, INC. | $41.33 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $35.87 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $35.07 | 2019 | |
| Neos Therapeutics, LP | $28.30 | 2019 | |
| Indivior INC. | $27.50 | 2019 | |
| Merck Sharp & Dohme LLC | $12.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Picone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.